SOLICITATION NOTICE
B -- Analysis of ERSPC Control Database
- Notice Date
- 8/20/2009
- Notice Type
- Presolicitation
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-90200-MM
- Archive Date
- 9/18/2009
- Point of Contact
- Melissa P Marino, Phone: 301-402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
marinome@mail.nih.gov, cr214i@nih.gov
(marinome@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Division of Cancer Control and Population Sciences (DCCPS), plans to procure on a sole source basis, an Analysis of the ERSPC Control Database for the Reconciliation of the PLCO and ERSPC Trial Results Using CISNET Models with the Institute of Cancer Research, Cancer Screening Evaluation Unit, SRD Building, Cotswold Road, Sutton Surrey, SM2 5NG United Kingdom. The contractor shall provide analyses of the European Randomized Study of Prostate Cancer (ERSPC) control database for the reconciliation of the Prostate, Lung, Colorectal, and Ovarian (PLCO) study and ERSPC trial resulting using Cancer Intervention and Surveillance Modeling Network (CISNET) models.. The North American Industry Classification System Code is 541990 and the business size standard in $7.0M. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). The period of performance is twelve (12) months from date of award. The CISNET is a consortium of NCI funded modelers whose purpose is to utilize simulation and other modeling techniques to understand the impact of cancer control interventions (i.e. screening, treatment, prevention) on national trends in cancer rates, and to inform national/regional/local decisions on the most efficient utilization of existing and emerging technologies and strategies for the control of cancer. The CISNET prostate group was engaged in collaborative efforts to quantify the efficacy of PSA while waiting for results on the efficacy from the two randomized trials for PSA screening: the ERSPC and the PLCO Cancer Screening Trial in the US. Recently, the New England Journal of Medicine published early results of these two trials. Because of the differences in the results of the two trials, the data are not immediately comparable. Modeling data from the trial represent a unique opportunity to reconcile results on the efficacy of PSA screening from the two trials. The purpose of this contract is to estimate PSA screening from the intervention and control arm of the ERSPC trial and to obtain prostate cancer incidence data to be used in the fitting and calibration of CISNET models. The contractor shall provide recommendations and guidance to the NCI to develop a model to estimate screening use patterns in the control arm of ERSPC (contamination), provide individual data from the intervention arm of ERSPC for estimation of screening frequencies, work with CISNET modelers to agree on output on PSA frequencies, document and provide prostate cancer incidence data for the intervention arm of ERSPC, and discuss and agree on outputs on cancer detection with modelers. The Cancer Screening Evaluation Unit (CSEU) at the Institute of Cancer Research is uniquely qualified to perform the work outlined in this contract. The Institute of Cancer Research in the UK is one of the world's leading cancer research organizations and is internationally renowned for the quality of its science. The Cancer Screening Evaluation Unit (CSEU) is internationally recognized for its screening evaluation research. The CSEU conducts studies on the efficacy of screening for cancer, especially of the breast, cervix, colorectal and prostate; this includes large-scale, long-term trials of screening for cancer in sites where it is not yet of proven benefit, evaluation of existing screening programmes, and development of evaluation methods. They are known for conducting high quality research on screening evaluation for prostate cancer. Their work on prostate cancer includes the management and analysis of the central database for the European Randomised Trial of Screening for Prostate Cancer (ERSPC), crucial for the successful completion of this contract. Most importantly, they are the sole access point to the central ERSPC database. Worldwide, there are only two large screening trials that were designed to finally evaluate the efficacy of PSA screening for prostate cancer in reducing mortality: the European Randomized Trial of Screening for Prostate Cancer (ERSPC) and the US Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. In 2003 the Cancer Screening Evaluation Unit of the United Kingdom Institute of Cancer Research took over the role of management and analysis of the central database of the ERSPC trial. The trial involves eight countries, and has recruited over 160,000 men in the core age group of 55-59 at entry. No other group in the world maintains the data, is the sole access point to the ERSPC centers and has the extensive knowledge of the ERSPC data, required for the successful completion of this contract. Dr. Sue Moss is the Associate Director of the CSEU and will be responsible for managing this work. CSEU and its team of researchers are leading experts in evaluation of cancer screening and have extensive knowledge of the ERSPC trial and the database. Dr. Sue Moss has also experience in micro-simulation modeling and has published extensively in the area of screening for prostate cancer. Her understanding of the ERSPC trial data, access to the data, and experience with micro-simulation modeling and statistical issues of screening trial data gives Dr. Sue Moss an exceptional background that allows her to understand the type of information that the CISNET models need and interpretation of the ERSPC data. Therefore, the CSEU at the Institute of Cancer Research is uniquely qualified to perform the work outlined in this contract. This is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow the researcher to determine if the party can perform this requirement. An original and one copy of the capability statement must be received in the contracting office on or before 11:00 am ET on September 3, 2009 to Melissa Marino, Contract Specialist. All questions must be in writing and can be faxed to 301-402-4513 or sent via email to marinome@mail.nih.gov. It is the vendor's responsibility to ensure questions have been received. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractors must be registered in and have valid certifications in the Central Contractor Registration (CCR), www.ccr.gov and the Online Representations and Certifications Application (ORCA) www.orca.bpn.gov. Please reference NCI-90200-MM on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-90200-MM/listing.html)
- Record
- SN01920851-W 20090822/090821002237-ab12458354fde85fa2f753b7e28d9ee5 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |